NEW YORK (GenomeWeb News) – Genomic cancer diagnostic services firm Kew Group today announced it has closed a private round of financing.

The Cambridge, Mass.-based firm did not disclose the amount of the round or how it will be used, and it did not respond to an e-mail seeking comment. However, in a document filed with the US Securities and Exchange Commission earlier this moth, Kew said that it raised $16.1 million toward a targeted goal of $30.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.